Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.l.a.

Chengdu Yiping Medical Science & Technology Co. Ltd

Institute of Pharmacology and Toxicology Academy of Military Medical Sciences Pla China

Institute of Pharmacology and Toxicology Academy of Military Mecical Sciences, P.l.a., China

Keliang Liu

Yuanjun Liang

Jiankun Qie

Ying Wang

Hai Feng Wang

Liang Xu

Huajin Dong

Zehui Gong

Qingbin Meng

Yufen Zhao

Jinbo Ma

Sicheng Li

Jianquan Zheng

Xiaoyu Xu

Dazhen Cai

Sijian Dong

Wenxia Zhou

Chunhui Qi

Wensheng Yu

Zhenkai Ding

Zhixia Yang

Qingsong Zhang

A medical adhesive with good biodegradable performance capable of undergoing crosslinking copolymerization, comprising a mono-alpha-cyanoacrylate and a bis-alpha-cyanoacrylic acid diol ester monomer molecule. The olefinic bonds in the mono-alpha-cyanoacrylate structure are polymerized in the presence of infinitesimal anions to form a solid 3D high polymer; the 3D high polymer is provided with degradation sites on the web-like backbone chain, with clear degradation path and absorbable degradation products. The medical adhesive can be used for wound adhesive, large area wound hemostasia, and visceral and soft tissue wound closure.

Biodegradable medical adhesive and preparation method and use thereof

The present invention relates to site-specific PEGylated linear salmon calcitonin analogs, or pharmaceutically acceptable salts thereof, process for their preparation, pharmaceutical compositions comprising them, and their use for the preparation of a medicament for the treatment or prevention of diseases associated with bone metabolism, e.g., osteoporosis.

Site-specific pegylated linear salmon calcitonin analogues

Disclosed are PEG-modified Exendin-4 analogs and uses thereof. In particular, disclosed are PEG-modified Exendin-4 analogs as shown in formula (I), i.e., PEG-M-X-(Ex-4), or pharmaceutically acceptable salts thereof, as well as Exendin-4 analogs as shown in formula (II), i.e., [Aa]Exendin-4, wherein the symbols are as defined in the specification. Further disclosed are methods for preparing PEG-modified Exendin-4 analogs, uses of PEG-modified Exendin-4 analogs, compositions comprising the same, as well as use of the Exendin-4 analogs in the preparation of the PEG-modified Exendin-4 analogs. In the PEG-modified Exendin-4 analogs, modification by polyethylene glycol occurs in a site-directed manner in the peptide chains of the Exendin-4 analogs. The PEG-modified Exendin-4 analogs can be used to prevent and/or treat diseases and/or symptoms related to decreased activity of GLP-1 receptors, such as type II diabetes.

Site-directed PEG-modified exendin-4 analogs and uses thereof

Polyethylene glycol modifications of thymosin alpha 1 (T&agr; 1-PEGs), their preparation process, the medicine composition containing them, and their application in the medicine for preventing and treating diseases related with immune deficiency and hypoimmunity, including hepatitis B, hepatitis C, hepatoma, malignant melanoma, non-small cell lung cancer, SARS, and AIDS etc.

Polyethlene glycol modifications of thymosin alpha-1

The instant invention relates to some tripeptide derivatives having activity against endothelin a process for preparing them, pharmaceutical composition containing the same and their use in prevention or treatment of some diseases associated with endothelin.

Endothelin antagonist

Growing community of inventors

Beijing, China

Keliang Liu